tislelizumab

Overview

Tislelizumab (BGB-A317) is a humanized monoclonal antibody that targets programmed death 1 (PD-1), a key immune checkpoint receptor expressed on T cells. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, tislelizumab restores antitumor immune activity that cancer cells exploit to evade immune surveillance. Engineered with a modified Fc region to minimize Fc gamma receptor binding on macrophages — a mechanism thought to reduce antibody-dependent cellular phagocytosis of T cells — tislelizumab is designed to preserve effector T cell function more effectively than earlier generation PD-1 inhibitors. Developed by BeiGene, the drug has received regulatory approval in China and select global markets for multiple indications including non-small cell lung cancer, hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma (ESCC).

As a PD-1 checkpoint inhibitor, tislelizumab belongs to the broader class of immune oncology agents that have transformed the treatment landscape for solid tumors over the past decade. Its clinical development has expanded across gastrointestinal malignancies, thoracic Cancers, and combination strategies with chemotherapy, radiotherapy, and targeted biologics — reflecting a growing emphasis on harnessing immunotherapy within multimodal treatment regimens.

Recent Publications Summary

Tislelizumab, a programmed death 1 (PD-1) checkpoint inhibitor, has been evaluated across multiple solid tumor types in combination with chemotherapy, targeted agents, and other immunotherapies. In gastrointestinal malignancies, neoadjuvant and perioperative tislelizumab-based regimens have shown promise in locally advanced gastric and esophageal squamous cell carcinoma (ESCC). The Mountain-02 trial demonstrated that perioperative tislelizumab plus chemotherapy significantly increased major pathological response rates compared with chemotherapy alone in patients with locally advanced gastric cancer, particularly in those with tumor-specific MHC class II (tsMHC-II)-positive disease (61.8% vs. 26.5%, p = 0.003), suggesting tsMHC-II as a predictive biomarker for immunotherapy benefit 42456653Jul. In ESCC, tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy was investigated as treatment for unresectable locally advanced disease 41962116Apr, and PET/CT-guided neoadjuvant tislelizumab plus chemotherapy or chemoradiotherapy showed efficacy in resectable ESCC 41770095Mar. For HER2-positive gastroesophageal adenocarcinoma, tislelizumab was combined with zanidatamab (a HER2-targeted bispecific antibody) plus chemotherapy, demonstrating encouraging efficacy and safety 42202319May42600568Aug.

In non-small cell lung cancer (NSCLC), tislelizumab has been evaluated across multiple treatment contexts. The RATIONALE-303, RATIONALE-315, and RATIONALE-312 trials established efficacy in second-line or later NSCLC, perioperative NSCLC, and extensive-stage small cell lung cancer (ES-SCLC), with outcomes including improved event-free survival and pathological responses 42412689Jul. The transportability of RATIONALE trial outcomes to European populations was assessed through outcome regression modeling, demonstrating that efficacy signals from predominantly Asian populations were comparable to predicted European benefit 42412689Jul. In the RATIONALE-307 trial of advanced squamous NSCLC, tislelizumab plus chemotherapy improved overall survival compared with chemotherapy alone, with concurrent improvements in patient-reported outcomes including global health status, cough, and dyspnea 42319531Jun. In advanced squamous NSCLC, ivonescimab, a bispecific PD-1/VEGF antibody, plus chemotherapy was compared with tislelizumab plus chemotherapy as first-line therapy in the HARMONi-6 trial, with ivonescimab demonstrating superior progression-free survival 42218899May. Tislelizumab combined with anlotinib was also evaluated as first-line therapy in advanced pulmonary sarcomatoid carcinoma, a highly aggressive NSCLC subtype 41894181Mar.

Beyond lung and gastrointestinal malignancies, tislelizumab has been investigated in other solid tumors. In epithelial ovarian cancer, the NAIVE trial evaluated neoadjuvant tislelizumab plus platinum-based chemotherapy compared with chemotherapy alone in patients with FIGO IIIC-IV disease, showing numerically prolonged progression-free survival (27.2 vs. 21.8 months; HR = 0.44, 95% CI 0.15–1.26) and higher 1-year and 2-year PFS rates, with superior tumor responses and R0 resection rates 42399240Jul. In very high-risk, nonmuscle-invasive bladder cancer, tislelizumab was combined with nanoparticle albumin-bound paclitaxel, with magnetic resonance imaging-derived radiomic phenotypes investigated as predictors of treatment response 42339693Jun. Tislelizumab was also evaluated as a component of combination immunotherapy in hepatocellular carcinoma, where it was combined with ociperlimab and a bevacizumab biosimilar (BAT1706) in the AdvanTIG-206 phase II trial for first-line treatment 42047833Apr.

To improve clinical feasibility and patient convenience, a subcutaneous formulation of tislelizumab was developed and evaluated in the phase 1 BGB-A317-103 study in patients with locally advanced or metastatic NSCLC. Population pharmacokinetic modeling demonstrated greater bioavailability with subcutaneous thigh administration compared with abdominal injection, supporting the selection of tislelizumab 300 mg every 3 weeks subcutaneously as an alternative to the intravenous 200 mg regimen 42337921Jun. These formulation advances may reduce logistical burden and resource demands associated with intravenous administration while maintaining comparable therapeutic exposure.

What Changes, What Holds

1. tumor-specific MHC class II expression identifies responders to neoadjuvant tislelizumab in gastric cancer
NEW DIRECTION MHC-II positivity substantially enriches for pathological response to tislelizumab plus chemotherapy in perioperative gastric cancer 42456653Jul, introducing immunophenotypic stratification absent from the Overview's account of combination approaches. biomarker-guided patient selection may improve efficacy outcomes in checkpoint-inhibitor-based regimens beyond the indications described in established practice.

2. Efficacy in NSCLC extends across perioperative, second-line, and small-cell treatment phases
REINFORCES Tislelizumab benefit spans perioperative, second-line, and extensive-stage small-cell contexts 42412689Jul42319531Jun, confirming the Overview's established role while broadening it across treatment phases. Transportability modeling supports comparable European applicability, though head-to-head comparison with ivonescimab (PD-1/VEGF bispecific) in first-line squamous NSCLC showed the bispecific superior 42218899May, establishing tislelizumab as effective but not optimal in that specific setting.

3. Tislelizumab combinations show activity in ovarian and bladder malignancies beyond established indications
NEW DIRECTION Epithelial ovarian cancer demonstrates response to neoadjuvant tislelizumab plus platinum chemotherapy with improved pathological responses and survival trends 42399240Jul, while nonmuscle-invasive bladder cancer responds to tislelizumab plus nab-paclitaxel with radiomic-enriched patient selection 42339693Jun. Ovarian and bladder applications expand the drug's scope beyond the Overview's listed indications. HCC continues advancing with triple-combination strategies including bevacizumab biosimilar 42047833Apr.

4. Subcutaneous tislelizumab via thigh injection provides adequate bioavailability with reduced logistical demands
NEW DIRECTION Subcutaneous 300 mg every 3 weeks achieves superior bioavailability versus abdominal injection and provides an alternative to intravenous 200 mg dosing 42337921Jun. As the Overview addresses no formulation or administration routes, subcutaneous delivery may reduce infusion-center burden and expand accessibility without apparent therapeutic compromise.

Overview update candidates: MHC class II biomarker stratification in gastric cancer; subcutaneous formulation as an administration route alternative.